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ew Insights
nto Improving
cute and Long-Term
utcomes of Carotid Stenting*
ay S. Yadav, MD, FACC
leveland, Ohio
arotid stenting is now a Food and Drug Administration-
pproved procedure for high surgical risk patients and has
enters for Medicare and Medicaid Services reimbursement
or symptomatic patients who are at high surgical risk. The
tenting and Angioplasty with Protection in Patients at
igh Risk for Endarterectomy (SAPPHIRE) randomized
rial demonstrated the superiority of carotid stenting with
mboli protection to endarterectomy in high surgical risk
atients, and there are currently three approved carotid
tents and emboli prevention devices in the U.S. (1). The
nterventional community can take some satisfaction in the
aturation and mainstreaming of carotid stenting; however,
uch work remains to be done, and the two studies
ublished in this issue of the Journal (2,3) contribute to the
dvancement of carotid stenting.
See pages 2384 and 2390
There have been a limited number of prospective multi-
enter carotid stenting studies published, and therefore the
arotid Revascularization with EV3 Arterial Technology
volution (CREATE) trial by Safian et al. (2) is an
mportant addition to the carotid literature. The CREATE
rial was a non-randomized study of carotid stenting with a
nique over-the-wire emboli protection filter. Only 30-day
ata is reported, and the technical success rate was good at
7.4%. The overall 30-day complication rate of 6.2% for
eath, stroke, and myocardial infarction (MI) was in the
eneral range for high surgical risk carotid patients. How-
ver, the results have to be interpreted with caution due to
he end point definitions; the standard all stroke 30-day end
oint was not used. Instead, only ipsilateral strokes and
rocedure-related contralateral strokes were considered,
hich would lead to some periprocedural contralateral strokes
ot being counted. Furthermore, a more liberal definition of
I, creatine kinase of three times normal, was utilized,
otentially excluding some MIs that were included in other
arotid stenting studies. The inclusion criteria were the gen-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio.rally accepted high surgical risk criteria and were similar to
he SAPPHIRE trial with the exception of the age defini-
ion, which was age 75 years instead of the age 80 years
sed in the SAPPHIRE trial. Further limitations of the
tudy are the lack of an independent data center or an
ngiographic core lab to verify the degree of stenosis.
This study does, however, provide several insights that
ave not been previously reported. A carefully conducted
ultivariate analysis indicates that the presence of symp-
oms, baseline renal insufficiency, and duration of filter
eployment are predictors of stroke. While the mean
uration of filter deployment was approximately 18 min,
atients with major strokes had a mean filter deployment
ime of almost 26 min. Furthermore, in patients with filter
urations of 20 min there was almost double the risk of
eath and stroke compared with patients with filter deploy-
ent times of 20 min. This provides the first systematic
vidence that filter deployment times, and by inference
verall procedure times, are important predictors of acute
utcomes in carotid stenting. Because the most difficult part
f carotid stenting is typically the guide catheter placement
nd filter placement, it is surprising that it still took an
verage of 18 min to complete the procedure after the filter
as deployed. This finding would suggest inexperienced
perators or a lack of appreciation of the need for speed after
he filter is deployed. This study drives home the point that
ll materials such as the stent and post-dilatation balloons
hould be prepared before filter deployment, and the pro-
edure should be finished with all due speed once the filter
s deployed. Typically, it should take no more than 5 to 10
in once the filter is deployed to complete stent deploy-
ent, post-dilatation, and capture and removal of the filter.
Another procedural insight from this study was regarding
he occurrence of hemorrhagic stroke. The major stroke rate
f 3.5% and the intracranial hemorrhage rate of 1.3% were
igher in this study than in other studies in high-risk
atients. This is particularly surprising because patients with
trokes within 30 days were excluded from this study, which
as not the case in other high surgical risk studies. The
uthors note that these strokes were not associated with
xcessive procedural anticoagulation, but specific data are
ot provided. Two of the patients were on concomitant
arfarin therapy, and one had poorly controlled hyperten-
ion. One patient potentially had hyperfusion syndrome.
The high incidence of intracranial hemorrhage in this
tudy highlights the importance of periprocedural patient
anagement. As we become better at reducing the risk of
schemic stroke, the relative importance of intracranial
emorrhage will increase. Hyperperfusion syndrome is an
mportant predictor of this catastrophic event after endar-
erectomy as well as carotid stenting (4). Hypertension,
evere stenosis, and severe contralateral disease have been
hown in a multivariate analysis to be predictors of hyper-
erfusion and intracranial hemorrhage (4). The periproce-
ural identification of patients at risk for hyperfusion and
c
h
s
t
t
p
r
l
p
t
T
1
t
c
b
T
s
r
d
t
o
m
s
t
m
t
s
i
d
p
e
t
o
a
t
r
s
p
t
m
p
c
e
o
t
g
c
R
m
d
y
R
1
2
3
4
5
2398 Yadav JACC Vol. 47, No. 12, 2006
Editorial Comment June 20, 2006:2397–8areful post-procedure management reduced the risk of
yperfusion and intracranial hemorrhage in a prospective
tudy (5). Reversal of heparin with protamine at the end of
he procedure and careful management of blood pressure for
he first week are important steps that can be taken in
atients at increased risk of hyperperfusion to reduce the
isk of hemorrhage.
Clark et al. (3) conducted the first systematic intravascu-
ar ultrasound (IVUS) study of carotid artery stenting and
rovided us with some important mechanistic insights into
he short- and medium-term behavior of carotid stents.
his study suffers from having been in the mid-to-late
990s and utilizing primarily the Wallstent (Boston Scien-
ific, Natick, Massachusetts). All of the currently approved
arotid stents are made from nitinol and have quite different
ehavioral characteristics than the elgiloy-based Wallstent.
he authors demonstrated great courage in conducting this
tudy before emboli protection was widely available and
eport no complications with the performance of IVUS both
uring the index procedure as well as at follow-up. Al-
hough the post-procedural stent expansion was poor, being
nly 70% by IVUS, there was considerable stent enlarge-
ent (49%) at six months. However, new intimal hyperpla-
ia increased proportionately being 37% at six months. As in
he coronaries, there was a relationship between the mini-
um luminal diameter (MLD) at the end of the procedure
o restenosis. In fact, MLD was the only predictor of
tenosis, with no correlation found for other variables
ncluding, surprisingly, gender, previous endarterectomy,
iabetes, or calcification.
There has been a tendency in current carotid stenting
ractice to leave the stent underdilated in order to reduce
mbolization. This study suggests that there may be a price
o pay in terms of restenosis if an adequate MLD is not
btained; unfortunately, it does not tell us what MLD isssociated with an acceptable risk of restenosis. It is possible
hat the behavior of nitinol stents may be different in this
egard, but the relationship between MLD and restenosis
hould apply to nitinol stents also.
These studies give us several insights into improving the
erformance of carotid stenting. Foremost, short procedure
ime and particularly filter deployment times are essential to
inimizing complications. The best way to insure short
rocedure times is with adequate operator training and
areful patient selection. Although avoiding procedural
mbolization is of paramount importance, it is essential to
btain a reasonable angiographic result and MLD in order
o avoid restenosis. Periprocedural management requires
reater attention if we are to continue to reduce the
omplications of carotid stenting.
eprint requests and correspondence: Dr. Jay S. Yadav, Depart-
ent of Cardiovascular Medicine/F 25, Cleveland Clinic Foun-
ation, 9500 Euclid Avenue, Cleveland, Ohio 44195. E-mail:
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